Navidea Biopharmaceuticals News

0,129 +4,03% +0,005 €
09:10:43 Uhr Frankfurt | Orderbuch | Mehr Kurse »
WKN: A1JSBX
ISIN: US63937X1037
US-Symbol: NAVB
Typ: Aktie

Navidea Biopharmaceuticals News

  
01.02.19 Navidea Biopharmaceuticals Announces Extension of NYSE American Listing Businesswire
24.01.19 Navidea Biopharmaceuticals Announces Decision by Ohio Supreme Court Businesswire
07.12.18 Navidea Biopharmaceuticals Announces Patent Extension for Lymphoseek® Businesswire
29.11.18 Navidea Biopharmaceuticals Appoints Dr. Michael Rosol as Chief Medical Officer Businesswire
27.11.18 Navidea Biopharmaceuticals Announces Presentation at the Radiological Society of North America (RSNA) 104th Scientific Assembly and Annual Meeting 2018 Businesswire
26.11.18 Navidea Biopharmaceuticals Appoints Dr. Kathy Rouan to Board of Directors Businesswire
11.04.14 Navidea Pharmaceuticals Inc. Analyst Report: Long Term Market Potential of Lymphoseek does not Justify Current Valuation by BrokerBank Securities, Inc. PR Newswire
13.08.13 Robbins Arroyo LLP Is Investigating the Directors and Officers of Navidea Biopharmaceuticals, Inc. PR Newswire
03.06.13 SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Navidea Biopharmaceuticals, Inc. PR Newswire
11.09.12 Navidea Biopharmaceuticals-​Aktie: "buy" - Ladenburg Thalmann Aktiencheck
11.09.12 Navidea Biopharmaceuticals-​Aktie: Kursziel gesenkt - Rodman & Renshaw Aktiencheck
22.08.12 Navidea Biopharmaceuticals-​Aktie: "buy" - ThinkEquity Partners Aktiencheck
31.07.12 Alseres Pharmaceuticals, Inc. Reports License of Altropane® Worldwide Rights to Navidea Biopharmaceuticals, Inc. PR Newswire
23.07.12 Navidea Biopharmaceuticals-​Aktie: vielversprechende Pipeline - Hot Stocks Investor Aktiencheck

Newssuche